Clinical trials are vital in developing and evaluating new treatments for children with rheumatologic diseases.
Studies currently being conducted by the PRCSG include:
| Title |
Sponsor |
| A Long-term, Multicenter, Longitudinal Post-marketing, Observational Registry to Assess Long Term Safety and Effectiveness of Humira (adalimumab) in Children with Moderate to Severe Active Polyarticular or Polyarticular Course Juvenile Idiopathic Arthritis (JIA) - STRIVE |
AbbVie |
| An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis |
Bristol-Myers Squibb |
| A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy |
Janssen Research & Development, LLC |
| A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus |
GlaxoSmithKline |
| A study to evaluate decreased dose frequency in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA) who experience laboratory abnormalities during treatment with tocilizumab |
Hoffman-La Roche |
| Long-Term extension study to evaluate the safety and efficacy of subcutaneous tocilizumab in patient with polyarticular-course and systemic juvenile idiopathic arthritis |
Hoffman-La Roche |
| Secukinumab Safety and Efficacy in JPsA and ERA |
Novartis Pharmaceuticals |
| A Long-term, Open-label Follow-up Study Of Tofacitinib For Treatment Of Juvenile Idiopathic Arthritis (Jia) |
Pfizer |
| Efficacy, Safety And Tolerability Of Tofacitinib For Treatment Of Polyarticular Course Juvenile Idiopathic Arthritis (Jia) In Children And Adolescent Subjects |
Pfizer |
| A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA |
Pfizer |
| Pediatric Arthritis Study of Certolizumab Pegol (PASCAL) |
UBC, Inc |
